To test whether VDR levels are down-regulated in more aggressive tumors, VDR and CD44 expression was assessed in fresh human tumor samples obtained from aggressive triple negative (TN) and estrogen receptor positive (ER+) tumors (Table 1). Here, VDR is linked to neoplasm.